CYCLO THERAPEUTICS, INC.: 10-Q filed 2024-05-15

Name: CYCLO THERAPEUTICS, INC.: 10-Q filed 2024-05-15
Creator: CYCLO THERAPEUTICS, INC.

What CYCLO THERAPEUTICS, INC. reported in its quarterly report filed 2024-05-15 (fiscal Q1 2024): 31 published measures, 64 facts as tagged in accession 0001437749-24-017038.

This filing

Form: 10-Q (quarterly report)
Filed: 2024-05-15
Fiscal period: fiscal Q1 2024
Accession: 0001437749-24-017038 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2024-03-31	7,163,890	USD
At 2023-12-31	13,247,538	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2024-03-31	610,014	USD
At 2023-12-31	4,757,007	USD
At 2023-03-31	-438,876	USD
At 2022-12-31	734,544	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2024-03-31	2,995,178	USD
At 2023-12-31	9,246,592	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-4,343,063	USD	91
2023-01-01 to 2023-03-31	-5,007,085	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-6,182,133	USD	91
2023-01-01 to 2023-03-31	-4,370,239	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-69,281	USD	91
2023-01-01 to 2023-03-31	3,741,997	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2024-03-31	-88,199,744	USD
At 2023-12-31	-83,856,681	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	28,585,228	shares	91
2023-01-01 to 2023-03-31	11,003,588	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-0.15	USD/shares	91
2023-01-01 to 2023-03-31	-0.46	USD/shares	90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	0	USD	91
2023-01-01 to 2023-03-31	0	USD	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2024-03-31	24,342	USD
At 2023-12-31	38,332	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	173,218	USD	91
2023-01-01 to 2023-03-31	91,668	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-5,121,062	USD	91
2023-01-01 to 2023-03-31	-5,007,132	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2024-03-31	6,570,072	USD
At 2023-12-31	12,318,257	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2024-03-31	6,536,369	USD
At 2023-12-31	8,468,047	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2024-03-31	3,670,646	USD
At 2023-12-31	4,856,530	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2024-03-31	71,322	USD
At 2023-12-31	122,379	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2024-03-31	242,530	USD
At 2023-12-31	254,352	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	190,627	USD	91
2023-01-01 to 2023-03-31	142,215	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	2,845,483	USD	91
2023-01-01 to 2023-03-31	3,398,167	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2024-03-31	28,614,384	shares
At 2023-12-31	28,556,072	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2024-03-31	88,806,896	USD
At 2023-12-31	88,610,832	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2024-03-31	569,476	USD
At 2023-12-31	890,949	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-4,343,063	USD	91
2023-01-01 to 2023-03-31	-5,007,085	USD	90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	2,177	USD	91
2023-01-01 to 2023-03-31	4,819	USD	90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	237,568	USD	91
2023-01-01 to 2023-03-31	47	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	777,999	USD	91
2023-01-01 to 2023-03-31	47	USD	90

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	756	USD	91
2023-01-01 to 2023-03-31	1,730	USD	90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	0	USD	91
2023-01-01 to 2023-03-31	1,334,034	USD	90

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-51,057	USD	91
2023-01-01 to 2023-03-31	76,233	USD	90

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-11,822	USD	91
2023-01-01 to 2023-03-31	-9,994	USD	90

Inspect the source

Entity: CYCLO THERAPEUTICS, INC. / CIK 0000922247
Captured: 2026-09-21T17:17:43.874Z
SEC response SHA-256: 00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))